Pfizer-Mylan Deal 'Well-Valued' for Mylan, Says Raffat

The transcript discusses the valuation and structure of the Mylan-Pfizer deal, highlighting its equity-based nature and potential regulatory concerns. It forecasts sales for the new company and examines Pfizer's growth outlook post-divestiture. The discussion also covers future deal prospects, a recent credit rating downgrade, and the potential impact of drug pricing policies on the companies involved.

What is the expected sales forecast for the new company formed by the merger?

What are the implications of the administration's proposals on drug pricing for Pfizer?